Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
111 hedge funds and large institutions have $1.09B invested in Avidity Biosciences in 2021 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 44 increasing their positions, 20 reducing their positions, and 8 closing their positions.
200% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 8
120% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 20
28% more capital invested
Capital invested by funds: $853M → $1.09B (+$241M)
17% more funds holding
Funds holding: 95 → 111 (+16)
5.52% more ownership
Funds ownership: 91.8% → 97.32% (+5.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$99M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$35.8M |
| 3 |
RI
RTW Investments
New York
|
+$17.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.6M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$14.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
-$29.7M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$22.5M |
| 3 |
DM
Deerfield Management
New York
|
-$13.8M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$10.5M |
| 5 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
-$5.63M |
RNAM Hedge Fund Activity: Q3 2021 in Review
111 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q3 2021, worth a combined $1.09B — up 28% from $853M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new RNAM positions and 8 closed out — a net gain of 16 holders — while 44 added to existing stakes and 20 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $99M. The largest seller was Matrix Capital Management Company, exiting entirely with an estimated $29.7M sold.
- 111 institutional investors held Avidity Biosciences (RNAM) as of Q3 2021, up from 95 in Q2 2021.
- Funds reported $1.09B of Avidity Biosciences stock for Q3 2021, up 28% quarter-over-quarter.
- 24 funds opened new Avidity Biosciences positions in Q3 2021 and 8 closed out, a net change of +16 holders.
- The largest Avidity Biosciences buyer in Q3 2021 was T. Rowe Price Associates, an estimated $99M added.
- The largest Avidity Biosciences seller in Q3 2021 was Matrix Capital Management Company, an estimated $29.7M sold.
Based on aggregated 13F filings for Q3 2021.